Enhancing antibiotic activity against Escherichia coli and Klebsiella pneumoniae with optimised pyridylpiperazine AcrAB-TolC efflux pump inhibitors
Published:
09/04/2026
Meurillon V, Jiménez-Castellanos JC, Vieira Da Cruz A, Sobieski C, Lèbre L, Piveteau C, Landry V, Leroux F, Deprez B, Willand N, Hartkoorn RC, Flipo M. Enhancing antibiotic activity against Escherichia coli and Klebsiella pneumoniae with optimised pyridylpiperazine AcrAB-TolC efflux pump inhibitors. Eur J Med Chem. 2026 Aug 5;319:119200. doi: 10.1016/j.ejmech.2026.119200. Epub ahead of print. PMID: 42586022.
Multidrug-resistant Enterobacterales, including Escherichia coli and Klebsiella pneumoniae, are classified as critical priority pathogens by the World Health Organization. A major contributor to resistance in these Gram-negative bacteria is the overexpression of the broad-spectrum RND-efflux pump AcrAB-TolC.
